RP-3 by Replimune for Melanoma: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Melanoma.

Is there a higher risk of depression among specific populations of patients with rheumatoid arthritis?

Researchers assessed the risk of depression following the diagnosis of rheumatoid arthritis (RA).

March 8, 2024

Google’s AI Model Listens to Your Cough to Detect Disease

[embedded content] What You Should Know: – Google Research has unveiled a groundbreaking advancement in healthcare technology with the introduction of HeAR, a bioacoustic foundation

August 21, 2024

UPMC Researchers Create Algorithm that Accurately Identifies High-Risk Surgical Patients

What You Should Know: Researchers and physicians at the University of Pittsburgh and UPMC used machine learning to create and deploy an accurate and flexible model for

July 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.